Personalized Medicine Biomarkers Market Size, Share, Trends & Forecast, 2026–2034

What Are Personalized Medicine Biomarkers?

Personalized medicine biomarkers are measurable biological indicators that aid in determining how a patient might respond to a certain disease or treatment method. They can come from different sources such as blood, tissues, genes, proteins, and any other biological material. Predictive biomarkers help in determining whether the patient is likely to benefit from a certain treatment. Genomic biomarkers analyze the genetic changes that are associated with disease susceptibility, treatment response, and medication sensitivity. By applying these biomarkers, doctors can choose treatment methods depending on the individual patient’s characteristics.

How Personalized Medicine Biomarkers Work?

Biomarkers used in personalized medicine assist physicians in understanding the characteristics of diseases and selecting personalized treatment based on the biological traits of the patient. The process usually comprises the following steps:

Sample collection: A biological sample is collected from the patient. The selected biomarker depends on the disease and the biomarker under investigation.

Biomarker identification: The collected samples are then used for testing specific biomarkers. Such tests could be done by genomic sequencing, molecular assays, or immunoassays.

Interpretation of the test results: The test results are then analyzed against known profiles of the same biomarkers. They help identify which markers are associated with disease risk, treatment response, and drug resistance.

Treatment selection: Based on the findings, the physician selects a treatment corresponding to the patient’s biomarker profile. This step is particularly important for addressing how do biomarkers guide cancer treatment. This is because certain biomarkers can indicate whether a patient responds to a specific therapy.

Treatment monitoring: Biomarkers can also be measured while undergoing treatment. The changes in biomarker levels may indicate treatment response or changes in disease.

Personalized Medicine Biomarkers Market Dynamics

Market dynamics highlight the key factors shaping demand for personalized medicine biomarkers. It covers growth drivers, testing costs, emerging trends, and new market opportunities.

Driver : Growing Integration of Biomarker Testing into Healthcare Systems

Biomarker testing is becoming more commonly used by healthcare providers in everyday practice to diagnose and make decisions regarding patient treatment using the test results. Cancer treatment is one key area where this integration is evident. Biomarker testing can identify patients who can benefit from targeted therapy treatments. Genomic testing has become more popular, allowing biomarker information to become more readily available when making decisions. Several  U.S. states have proposed or implemented legislation to facilitate better access to tests. This is reflected in efforts such as Connecticut mandating that health insurance plans provide biomarker tests starting January 2026 (source: cga.ct.gov). This development is indicative of efforts being made to reduce gaps within biomarker testing insurance coverage law. As coverage expands, more medical practitioners can integrate testing into their clinical practices. This can support early treatment decisions. It can also enable greater application of personalized medicine biomarkers within different medical facilities.

Driver : Rising Prevalence of Chronic Diseases

The rising burden of chronic diseases has raised the demand for tools that could help in diagnosing and making treatment decisions accurately. Diseases like cancer, cardiovascular diseases, diabetes, and neurological disorders usually vary between individuals. The biomarkers help distinguish these variations. Furthermore, the biomarkers can assist in monitoring these diseases and deciding on treatments. This requirement has become essential as populations grow older. Chronic diseases make up a larger portion of the total disease burden in the world. As reported by the WHO in October 2026, 74% of the deaths recorded globally in 2023 were due to non-communicable diseases. This is an increase from 58% in 2000 (source: who.int). Cancer is still a significant contributor to the disease burden. WHO reported an estimated 20.6 million cancer cases diagnosed in 2024 (source: who.int). With an increasing number of individuals requiring medical care in the long run, there is rising demand for the tests that help characterize the disease.

Restraints and Challenges : Reimbursement and Cost Barriers for Biomarker Testing

Reimbursement remains a challenge with some of the biomarker tests. The degree of reimbursement varies between insurance plans. Reimbursement may not be total for certain tests. The out-of-pocket expenses may increase in case of partial reimbursement. The new testing methods tend to make the cost of healthcare more expensive. Costs increase if more than one test is necessary. Emerging biomarker tests may require special conditions to be covered by insurance. Solid clinical data are needed before the reimbursement is granted. This makes the widespread implementation of new tests even more difficult. Budget limitations may also limit healthcare providers' ability to implement advanced testing methods. Small hospitals can be particularly affected by this. The lack of reimbursement limits patient access to testing. It may have an effect on the implementation of biomarkers in practice.

Trend : Growing Use of Biomarkers in Drug Discovery and Development

The use of biomarkers is becoming increasingly common in drug development. Scientists use biomarkers to detect biological changes linked to a disease. They can use them to determine which patients can qualify for the novel treatment. The data obtained from the biomarkers can help in designing the clinical trials. This approach supports the development of biomarker-guided therapy. It also helps expand the adoption of targeted therapy for diseases characterized by particular molecular signatures. The information obtained from the biomarkers can be useful during different phases of the drug development process. The use of biomarkers is also enabling the association of a new medicine with the patients who need it.

Trend : Increased Use of Liquid Biopsy for Personalized Care

Liquid biopsy is increasingly used as an alternative to biomarker testing. The technique uses blood samples to track biological markers released by tumors or other abnormal cells. This may reduce the need to collect new samples in some cases. Liquid biopsy can be applied when collecting tissue samples is not possible. This approach is especially valuable in oncology. Such tests can help clinicians monitor changes at the molecular level throughout the treatment process. This can prove to be helpful when a patient’s condition changes over the course of treatment. Further improvements in testing techniques are making it easier to detect tiny traces of biological markers. Greater implementation of liquid biopsy will increase access to biomarker data and enable regular tests in personalized treatments.

Opportunities : Development of Multi-Biomarker Testing Panels

Multi-biomarker panels can create new opportunities in the field of personalized medicine. These panels can analyze multiple biomarkers from a sample taken from a single patient. This can provide a more comprehensive evaluation of the biological makeup of a particular patient. At the same time, it can save some patients the trouble of taking multiple tests. These panels can support treatment decisions when a single biomarker is not sufficient for the purpose. Recent advancements in molecular testing have been instrumental in making such panels easier to develop. Wider adoption may lead to increased demand for advanced test platforms. It can encourage the application of individualized tests in other areas of practice. This creates opportunities for companies developing multi-biomarker testing products.

Opportunities : Expansion of Biomarker Testing in Preventive Care

The use of biomarkers has potential applications within preventive medicine. The tests can be used to determine changes that occur before symptoms become more noticeable. This can facilitate the early assessment of health risks. Doctors can use the information about the markers to track changes over time. A growing focus on preventive medicine is expected to support the demand for these tests. Another driver of demand is patients' growing interest in health information based on their individual biology. Using biomarkers in preventive medicine will increase the application field for these tests. It is also expected to drive the need for tests that are geared towards health monitoring purposes.

Opportunities : Increased Use of AI in Biomarker Discovery

Artificial intelligence (AI) is providing new ways of increasing the speed and accuracy of the process of discovering biomarkers. Through machine learning models, researchers can sift through biological data in order to identify patterns that are associated with certain conditions. AI can also assist scientists in evaluating relationships between genes and other biological signals. This way, the biomarker can be identified at an earlier stage of the investigation. The use of AI for analyzing biological data might decrease the time required to evaluate such datasets. This can increase the efficiency of biomarker research for laboratories and other organizations conducting scientific research. The increasing use of AI in biological research is expected to boost the need for specialized platforms.

FDA Approved Companion Diagnostics 2026

The FDA companion diagnostic list by biomarker highlights approved tests that support treatment selection based on specific molecular and genetic markers. Many of these tests support an oncology companion diagnostic approach by identifying biomarkers linked to cancer therapies.

Date	Companion Diagnostics (Manufacturer)	Indication / Sample Type	Therapy	Biomarker	PMA / Supplement
04 Sep 2026	Guardant360 CDx (Guardant Health)	Breast cancer / Plasma	Etcamah (camizestrant)	ESR1 mutations	P200010/S024
25 Aug 2026	PATHWAY anti-HER-2/neu (4B5) and VENTANA HER2 Dual ISH (Ventana Medical Systems)	Gastroesophageal adenocarcinoma	Ziihera (zanidatamab-hrii)	HER2 overexpression	P990081/S060; P190031/S016
14 Aug 2026	TruSight Oncology Comprehensive (Illumina)	Thyroid and medullary thyroid cancer / Tissue	Retevmo (selpercatinib)	RET alterations	P230011/S006
30 Jul 2026	PGDx elio tissue complete CDx (Personal Genome Diagnostics)	Melanoma / Tissue	BRAF inhibitors and BRAF/MEK inhibitor combinations	BRAF V600E/V600K	P250036
01 Jul 2026	PD-L1 IHC 28-8 pharmDx (Agilent)	Esophageal squamous, gastric, GEJ and esophageal adenocarcinoma / Tissue	Opdivo / Opdivo Qvantig	PD-L1, CPS ≥1	P150025/S018
12 Jun 2026	VENTANA PTEN (SP218) RxDx Assay (Roche)	Metastatic hormone-sensitive prostate cancer / Tissue	Truqap (capivasertib)	PTEN loss	P250031
10 Jun 2026	Guardant360 CDx (Guardant Health)	NSCLC / Plasma	Hernexeos (zongertinib)	HER2 activating mutations	P200010/S027
27 May 2026	FoundationOne CDx and FoundationOne Liquid CDx (Foundation Medicine)	Metastatic castrate-resistant prostate cancer / Tissue and plasma	Talzenna with Xtandi	HRR gene alterations	P170019/S060; P190032/S029
27 May 2026	FoundationOne CDx (Foundation Medicine)	Colorectal cancer / Tissue	Erbitux (cetuximab) and Vectibix (panitumumab)	KRAS/NRAS wild-type	P170019/S057
19 May 2026	Guardant360 Liquid CDx (Guardant Health)	Breast, colorectal and NSCLC / Plasma	Orserdu, Inluriyo, Braftovi with cetuximab, Tagrisso, Rybrevant, Lumakras and Enhertu	ESR1, BRAF V600E, EGFR, KRAS G12C and HER2	P250027
15 May 2026	PATHWAY anti-HER-2/neu (4B5) and VENTANA HER2 Dual ISH (Ventana Medical Systems)	Breast cancer / Tissue	Enhertu	HER2 overexpression/amplification	P990081/S058; P190031/S015
12 May 2026	FoundationOne CDx (Foundation Medicine)	NSCLC / Tissue	Tepmetko (tepotinib)	MET exon 14 skipping	P170019/S067
01 May 2026	Guardant360 CDx (Guardant Health)	Breast cancer / Plasma	Veppanu (vepdegestrant)	ESR1 mutations	P200010/S025
10 Mar 2026	Myriad myChoice CDx (Myriad Genetic Laboratories)	Ovarian cancer / Tissue	Zejula (niraparib)	BRCA1/2 and genomic instability	P190014/S011
10–11 Feb 2026	PD-L1 IHC 22C3 pharmDx (Agilent)	Ovarian, esophageal and GEJ carcinoma / Tissue	Keytruda (pembrolizumab)	PD-L1, CPS ≥1	P150013/S032; P150013/S033
15 Jan 2026	Guardant360 CDx (Guardant Health)	Colorectal cancer / Plasma	Braftovi with Erbitux	BRAF V600E	P200010/S026

Source: Polaris Market Research Analysis

Segment Insights

Personalized Medicine Biomarkers Market by Application

The treatment selection segment accounted for the largest market share of 51.8% in 2025. Biomarker testing provides physicians with data to choose treatments that suit the biological features of the disease in patients. The test may reveal if a patient has a marker of the effectiveness of a particular therapy. This assists doctors in making decisions about whether a treatment is suitable for a specific patient. As targeted medications become more common, the need for biomarker testing to help choose treatments is rising. Biomarker testing is increasingly used in several disease areas because treatment effectiveness varies from patient to patient. Biomarker testing can help minimize the use of treatments whose efficacy will be low for certain patients. Rising use of biomarker-based treatment options is driving demand for biomarker testing services. All these factors contribute to the leading position of the treatment selection segment.

The early detection/ screening segment is projected to grow at an 14.4% CAGR. Biomarker testing can help determine any biological change before the symptoms are visible. This aids in early assessment of any disease risk. Biomarkers can also provide information that might be used by healthcare professionals to determine if there is a need for further diagnosis of the patient. The emphasis being placed on preventive healthcare is driving demand for test products that identify health changes at early stages. Development in molecular testing is enhancing the ability to detect certain biological markers from patient samples. This leads to the wider application of biomarker tests for screening purposes. Early detection also allows healthcare professionals adequate time to conduct further assessment of the patient's condition. The increasing application of screening-based biomarker tests is supporting the growth of the early detection screening segment.

Personalized Medicine Biomarkers Market by Indication

The oncology segment accounted for an 35.7% personalized medicine biomarkers market share in 2025. Cancer is a major research area for biomarkers as tumors may differ from one another in biological properties. Biomarkers may be used to categorize tumors depending on their biological properties. The information obtained during the test allows identification of certain genetic and molecular alterations that occur in cancer cells. Biomarker testing can also be used for the characterization of the disease at various stages of its development. The growing number of cancer biomarkers has expanded the range of available clinical tests. With advances in genomics and molecular technologies, biomarkers may become easier to detect. Increased interest in disease characterization is expected to support the use of personalized medicine biomarkers in oncology and the breast cancer therapy market.

The diabetes segment is projected to witness the fastest growth at an 17.1% CAGR. Diabetes biomarker research is expanding beyond traditional markers utilized for the evaluation of the disease. Researchers are exploring biological markers that provide deeper insights into the process of disease formation. These markers can be helpful in distinguishing patients who have identical symptoms. Biomarker tests are being looked at as an approach to assess the risk of developing complications. Increased diabetes prevalence is driving the demand for innovative solutions in patient evaluation. Molecular advances are expanding the pool of candidate biomarkers. A greater focus on personalized disease diagnosis may also help this technology gain acceptance in diabetes treatment. These shifts create opportunities for personalized medicine biomarkers in the diabetes market segment.

Technologies Enabling Biomarker-Guided Care

Several technologies support biomarker-guided care by detecting genetic, molecular, and protein-based changes from patient samples. These tools help identify disease characteristics and inform clinical decisions.

Technology	What it Detects	Typical Sample	Example on the FDA List	Best Suited To
Comprehensive genomic profiling (NGS)	Mutations, fusions, copy number changes, TMB, and MSI	Tissue or plasma	FoundationOne CDx; TruSight Oncology Comprehensive	Broad tumor profiling
PCR-based assays	Specific gene mutations	Tissue or plasma	cobas EGFR Mutation Test v2; therascreen PDGFRA RGQ PCR Kit	Targeted mutation detection
Immunohistochemistry (IHC)	Protein expression	Tissue	PD-L1 IHC 22C3 pharmDx; PATHWAY HER2 (4B5)	Proteomics-based biomarker assessment
In situ hybridization	Gene amplification	Tissue	VENTANA HER2 Dual ISH	HER2 amplification assessment
Liquid biopsy / ctDNA testing	Tumor-derived genetic alterations	Plasma	Guardant360 CDx; FoundationOne Liquid CDx	Less-invasive molecular testing
ctDNA MRD companion diagnostic testing	Residual tumor DNA after treatment	Plasma	Signatera CDx	Molecular residual disease detection

Source: Polaris Market Research Analysis

Real-World Use Cases of Personalized Medicine Biomarkers

Personalized medicine biomarkers find uses in different stages of patient care. They support treatment decisions and disease monitoring. They also enable residual disease assessment and inherited risk evaluation. The table below details the real-world use cases of these biomarkers.

Real-world use case	Clinical application	Value of biomarker information
Matching patients to targeted therapy	A patient is tested before starting a targeted medicine.	Helps determine whether the patient has the required biomarker.
Selecting immunotherapy	Biomarker results are reviewed before certain immunotherapies are prescribed.	Helps identify patients who may respond to treatment.
Monitoring treatment response	Biomarker levels are measured during treatment.	Changes in the biomarker can provide information on treatment response.
Detecting residual disease	Biomarker testing is performed after surgery or other treatment.	Can help identify molecular signs of remaining disease.
Identifying inherited disease risk	Genetic biomarkers are assessed in patients with a relevant family or clinical history.	Provides information about potential inherited risk.
Guiding treatment changes	Biomarker results are reviewed when disease characteristics change.	Can support a decision to adjust or reconsider treatment.

Source: Polaris Market Research Analysis

Traditional vs Personalized Medicine

Traditional medicine follows treatment modalities based on common disease patterns, while personalized medicine utilizes patient-specific information. Differences between the two treatment methods have been highlighted in the following table.

Characteristic	Traditional Medicine	Personalized Medicine
Approach to Treatment	Relies on standard treatment procedures	Uses patient-specific information
Evaluation of the Patient	Primarily focused on the symptoms and findings	Includes molecular and genetic information
Choice of treatment	Chosen according to treatment protocols	Treatment is chosen based on patient biomarkers
Response to drugs	Patients are considered to respond similarly to the treatment	Takes into account differences in response to the drug
Classification of the disease	Classified based on clinical information	Molecular characteristics can also be used to classify
Monitoring of the treatment	Based on the symptoms and standard clinical tests	Can incorporate individual genetic or biological markers
Evaluation of risks	Generic risk factors are considered	Can also use genetic/biological risk factors
Decision making	Follows broadly applicable treatment pathways	Treatment decision-making can be individualized

Source: Polaris Market Research Analysis

Regional Insights

North America

North America accounted for the largest personalized medicine biomarkers market share of 51.3% in 2025. There is an established healthcare infrastructure that encourages the use of advanced diagnostic testing. Biomarkers in the U.S. biomarkers market are used across several medical sectors. Additionally, a large number of laboratories and healthcare providers in the U.S. provide genomic and molecular diagnostic test services. Coverage policies may affect the accessibility of such tests to patients. There have been some recent policy developments towards increased access to biomarker tests. Such efforts can help remove cost-related barriers for patients requiring biomarker tests. In addition to this, active research in the field of biomarkers is helping in the discovery of new biomarkers. Major pharmaceutical and diagnostic companies are another factor boosting the regional market. Canada is also increasing the use of precision medicine approaches through its healthcare and research systems.

Asia Pacific

The personalized medicine biomarkers market Asia Pacific is projected to witness the fastest growth at an 15.8% CAGR. Asia Pacific has emerged as an important market for personalized medicine biomarkers. Countries like China, Japan, South Korea, India, and Australia have increased the use of genomic and molecular testing. There has been increased adoption of advanced testing techniques by healthcare professionals to aid in improved diagnosis of patients. Genomic research is growing in the region. There has been increased funding by the Chinese government for precision medicine and genomic testing research. The use of genomic testing has become widespread in clinical practices in Japan. Molecular diagnostics are increasingly becoming available in India through private laboratories and clinics. Moreover, there is a sizable number of patients in the region, which supports biomarker research and development. Increased spending on healthcare is expected to drive the uptake of advanced testing services.

Europe

The Europe personalized medicine biomarkers market accounted for an 13.9% share in 2025. This region has a robust scientific foundation in genomics and molecular diagnostics. In addition, health care facilities in European nations are increasingly relying on biomarker tests during patient treatment processes. Personalized medicine is being promoted by the European Union through its various research projects and initiatives centered around genomic information and precision medicine. Countries that have developed the capacity to conduct molecular testing include Germany, France, the UK, and Italy. Increased use of specific treatments is creating further demand for companion diagnostics. Improvements in laboratory infrastructure are also increasing access to advanced tests.

Latin America

The Latin America personalized medicine biomarkers market is projected to grow at an 12.9% CAGR. Latin America is gradually adopting personalized medicine biomarkers due to the rise in the utilization of molecular diagnostics by healthcare providers. In countries like Brazil, Mexico, and Argentina, there is an expansion in the availability of sophisticated laboratory tests. In addition, awareness about precision medicine is contributing to the demand for biomarker-based tests. The improvements in the healthcare systems are enabling healthcare providers to offer genomic and molecular tests. There is rising research being carried out regarding cancers and genetic disorders. However, access to healthcare facilities and high testing costs remain challenges across the region. Increased focus on diagnostic laboratories and research can help facilitate the adoption of personalized medicine biomarkers in Latin America.

Middle East & Africa

The Middle East & Africa personalized medicine biomarkers market is anticipated to grow at an 13.6% CAGR. The UAE and Saudi Arabia are working on their genomics projects and are increasing the availability of genetic testing. In addition, South Africa has already conducted research on genomics and molecular diagnostics. The testing of biomarkers is becoming increasingly popular in those regions where genetic data can be helpful in making medical decisions. Medical facilities are enhancing their molecular testing through the development of specialized labs. However, access to these services remains unequal across countries because of differences in healthcare resources and testing infrastructure. Even so, efforts in genomics and diagnostics are contributing to the development of the foundation for broader biomarker use in the region.

Key Players and Competitive Landscape

The personalized medicine biomarkers market includes diagnostic firms, biotechnology companies, pharmaceuticals, and specialist testing companies. Market competitiveness depends on the ability to develop effective biomarker tests and use them clinically. Companies are focused on developing genomic testing technologies and companion diagnostics for personalized medicine. The industry also sees collaborations between diagnostic firms and drug companies, especially for biomarker tests related to specific therapies. Regulatory clearance remains important for market competitiveness. This is because clinical use depends on evidence of test performance and clinical value. Companies also aim to grow their testing menus and improve access to biomarker tests. There are differences in the strategic priorities of market players. Some personalized medicine biomarkers market key players focus on laboratory testing. Others concentrate on the development of diagnostic platforms or solutions for particular diseases.

Vendor Positioning

Company	Positioning	Flagship Offering
Abbott Laboratories	Molecular and clinical diagnostics for therapy selection and disease monitoring	Alinity m Molecular System; Abbott molecular companion diagnostic solutions
Alamar Biosciences, Inc.	Precision proteomics and fluid biomarker detection	NULISA Proteomics Platform; ARGO HT System
AstraZeneca PLC	Biopharmaceutical company using biomarkers to support targeted therapy development	Tagrisso and EGFR biomarker testing
Becton, Dickinson and Company	Automated molecular diagnostics and PCR-based testing	BD MAX System
F. Hoffmann-La Roche Ltd	Companion diagnostics and pathology solutions for precision medicine	VENTANA HER2 (4B5); PATHWAY HER2/neu (4B5); VENTANA MMR RxDx
Foundation Medicine, Inc.	Comprehensive genomic profiling and companion diagnostics	FoundationOne CDx; FoundationOne Liquid CDx
Fujirebio Europe NV	Immunoassays and biomarker testing for neurological and other diseases	Lumipulse assays and automated immunoassay systems
Informed Medical Decisions, Inc.	Genetic counseling and genomic testing support services	InformedDNA genetic counseling and precision health services
Johnson & Johnson Innovative Medicine	Targeted therapy development supported by biomarker and companion diagnostic strategies	BALVERSA with FGFR3 biomarker testing
Laboratory Corporation of America Holdings	Clinical genomic profiling and precision oncology testing	OmniSeq INSIGHT
Pfizer Inc.	Targeted drug development supported by biomarker-based patient selection	TALZENNA with BRCA/HRR biomarker testing
QIAGEN N.V.	Molecular testing and companion diagnostics for targeted therapies	therascreen KRAS RGQ PCR Kit; therascreen FGFR RGQ RT-PCR Kit
Quest Diagnostics Incorporated	Clinical laboratory testing, genomic profiling, and companion diagnostic services	Comprehensive genomic profiling; Haystack MRD
Thermo Fisher Scientific Inc.	NGS platforms and companion diagnostic solutions for biomarker-driven care	Oncomine Dx Target Test; Oncomine Dx Express Test

Source: Polaris Market Research Analysis

Industry Developments

• August 2026: QIAGEN launched QIAsymphony Connect for automated clinical nucleic acid extraction. The platform is intended for workflows involving liquid biopsy and other molecular tests. (source: qiagen.com)
• April 2026: Roche announced plans to acquire SAGA Diagnostics. The deal adds SAGA’s Pathlight molecular residual disease testing technology to Roche’s diagnostics portfolio. (source: roche.com)

Future Outlook

The personalized medicine biomarkers market is increasingly moving towards detailed patient profiling. With improvements in genomic and molecular tests, it may be possible to identify biomarkers associated with individual disease profiles. The improved access to testing may also be seen due to advances in laboratory technology. Biomarker data can help healthcare professionals make informed treatment decisions and keep track of their patients' health condition. New biomarker research will increase biomarker use across different diseases. The market can also benefit from the development of hyper personalized medicine, which emphasizes therapeutic options based on highly specific patient characteristics.

Research Methodology

Polaris estimates the personalized medicine biomarkers market using a combined top-down and bottom-up approach. Secondary research covers regulatory records, including the FDA companion diagnostic list, company annual reports, investor presentations, clinical literature, scientific publications, and public health data from organizations such as the World Health Organization.

Primary research includes interviews with industry participants across diagnostic companies, reference laboratories, and clinical organizations. Market estimates are developed using company and segment revenue data and are checked against available pricing, test volume, and adoption information.

The figures are then reconciled by application, indication, and region. Forecasts from 2026 to 2034 consider market drivers, restraints, and relevant regulatory factors. Information is cross-checked through multiple sources before the final estimates are reviewed and published. Data is refreshed when material events occur, and the page change log records each update.

Personalized Medicine Biomarkers Market Segmentation

By Indication Outlook (Revenue – USD Billion, 2021–2034)

• Oncology
  • By Type
    • Breast Cancer
    • Lung Cancer
    • Colon Cancer
    • Others
  • By Circulating Biomarkers
    • Circulating Tumor Cells(CTCs)
    • Circulating Cell-free DNA(cfDNA)
    • Extracellular Vesicles (EVs)
    • Other Circulating Biomarkers
• Neurology
• Diabetes
• Autoimmune Diseases
• Cardiology
• Others

By Application Outlook (Revenue – USD Billion, 2021–2034)

• Early Detection/Screening
• Diagnosis
• Treatment Selection
• Monitoring

By Regional Outlook (Revenue – USD Billion, 2021–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Personalized Medicine Biomarkers Market Report Scope

Report Attributes	Details
Market Size Value in 2025	USD 24.88 billion
Market Size Value in 2026	USD 28.17 billion
Personalized Medicine Biomarkers Market Forecast 2034	USD 77.37 billion
CAGR	13.4% from 2026 to 2034
Base Year	2025
Historical Data	2021–2024
Forecast Period	2026–2034
Quantitative Units	Revenue in USD billion and CAGR from 2026 to 2034
Report Coverage	Revenue Forecast, Market Competitive Landscape, Growth Factors, and Industry Trends
Segments Covered	By Application By Indication
Regional Scope	North America Europe Asia Pacific Latin America Middle East & Africa
Competitive Landscape	Personalized Medicine Biomarkers Industry Trends Analysis (2025) Company profiles/industry participants profiling includes company overview, financial information, product/service benchmarking, and recent developments
Report Format	PDF + Excel
Customization	Report customization as per your requirements with respect to countries, regions, and segmentation.

Source: Polaris Market Research Analysis